Posted by Michael Wonder on 22 Jan 2021
ICER publishes evidence report on therapies for high cholesterol
22 January 2021 - The evidence suggests that inclisiran can substantially lower LDL-C with limited safety concerns, and with a less frequent regimen that may enhance therapy adherence; ICER recommends an annual health-benefit price benchmark range of $3,600-$6,000.
The Institute for Clinical and Economic Review (ICER) today released an Evidence Report assessing the comparative clinical effectiveness and value of inclisiran (Novartis), bempedoic acid (Nexletol, Esperion Therapeutics), and bempedoic acid/ezetimibe (Nexlizet, Esperion Therapeutics) for treating heterozygous familial hypercholesterolemia and for secondary prevention of atherosclerotic cardiovascular disease.
